In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IBIDS database updated (ibid.)

This article was originally published in The Tan Sheet

Executive Summary

Office of Dietary Supplements and USDA Food & Nutrition Information Center database has added 30,000 new records, bringing total to 730,000 citations, according to an Aug. 18 release. Collection was last updated in 2001 (1"The Tan Sheet" Dec. 24, 2001, In Brief). As part of five-year anniversary celebration, database has been redesigned to include images and chemical structure of amino acids. In the next five years, plans include adding records from additional databases; creating and including keywords; and adding more consumer-oriented material...

You may also be interested in...

IBIDS database

International Bibliographic Information on Dietary Supplements database of vitamin, mineral, botanical articles and published studies now contains 639,122 citations, 75% of which include abstracts. Run by NIH Office of Dietary Supplements, IBIDS began with 250,000 citations (1"The Tan Sheet" Jan. 11, 1999, p. 16)...

Amgen’s Mvasi Biosimilar Survives Restraining Order Bid Again

Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.

Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.  





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts